Diversity of lipid-based polyene formulations and their behavior in biological systems

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 1, 1997, Pages 81-92

  Wasan, K M ^a   Lopez Berestein, G ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; HIGH DENSITY LIPOPROTEIN; LIPID TRANSFER PROTEIN; LIPOPROTEIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; NYSTATIN; PHOSPHOLIPID; POLYENE;

CONFERENCE PAPER; DRUG DISTRIBUTION; DYSLIPIDEMIA; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; PARTICLE SIZE; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY; LIPOPROTEINS; LIPOSOMES; MYCOSES; NYSTATIN; PHAGOCYTES;

EID: 0031045687     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575125     Document Type: Conference Paper

References (87)

1. Poznansky MJ, Juliano RL: Biological approaches to the controlled delivery of drugs: a critical review. Pharmacology Reviews 1984, 36: 277-336.
2. Juliano RJ, Layton D: Characteristics and biomedical applications. In: Juliano RJ (ed): Drug delivery systems. Oxford University Press, London, 1980, p. 189-211.
3. Juliano RL: Liposomes as a drug delivery system. Trends in Pharmacological Sciences 1981, 2: 39-59.
4. Szoka F, Papahadjopoulos D: Physical structure to therapeutic applications. In: Szoka F, Papahadjopoulos D (ed): Liposomes. Eisevier, Amsterdam, 1981, p. 51-82.
5. Juliano RJ: Drug delivery systems. In: Juliano RJ (ed): Liposomes. Marcel Dekker, New York, 1983, p. 53-86.
6. Gregoriadis G: Targeting of drugs: implications in medicine. Lancet 1981, ii: 241-246.
7. Gregoriadis G, Allison A: Liposomes as drug delivery systems. In: Gregoriadis G (ed): Liposomes in biological systems. John Wiley and Sons, Chichester, UK, 1980, p. 277-301.
8. Poste G: Liposome targeting in vivo: problems and opportunities. Biological Cell 1983, 47: 19-37.
9. Poste G, Kirsh R: Site-specific (targeted) drug delivery in cancer therapy. Biotechnology 1983, 1: 869-878.
10. Olson F, Mayhew E, Maslow D, Rustum R, Szoka F: Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. European Journal of Cancer and Clinical Oncology 1982, 18: 167-176.
11. Litzinger DC, Huang L: Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic application. Biochimica et Biophysica Acta 1992, 1113: 201-227.
12. Curr MI, James A: Study of phospholipids. In: Curr MI (ed): Lipid biochemistry. Chapman & Hall, London, 1980, p. 2-22.
13. Lopez-Berestein G: Liposomes as carriers of antifungal drugs. Annals of the New York Academy of Sciences 1988, 544: 590-597.
14. Weinstein JH, Lesserman LD, Henkart PA, Blumenthal R: Antibody mediated targeting of liposomes. In: Weinstein JH (ed): Targeting of drugs. Plenum Press, New York, 1982, p. 185-202.
15. Fendler JH: Optimizing drug entrapment in liposomes: chemical and biophysical considerations. In: Gregoriadis G (ed): Liposomes in biological systems. John Wiley and Sons, Chichester, UK, 1980, p. 87-100.
16. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z: Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Research 1982, 42: 4734-4739.
17. Rahman A, Kessler A, More N: Liposomal protection of adriamycin-induced cardiotoxicity. Cancer Research 1980, 40: 1532-1537.
18. Forssen EA, Tokes ZA: Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proceedings of the National Academy of Sciences of the USA 1981, 78: 1873-1877.
19. Durrington PN: Hyperlipidemia: diagnosis and management. In: Durrington PN (ed): Lipoproteins and Lipids. Wright, London, 1989, p. 255-277.
20. Davis RA: Lipoprotein structure and secretion. In: Vance DE, Vance J (ed): Biochemistry of lipids, lipoproteins, and membranes. Elsevier, New York, 1991, p. 403-426.
21. Harmony JAK: Study of lipids and lipoproteins. In: Harmony JAK (ed): Biochemistry and biology of plasma lipoproteins. Marcel Dekker, New York, 1986: 403-433.
22. Mbewu A, Durrington PN: Lipoproteins involved in tissue repair. Atherosclerosis 1990, 85: 1-8.
23. Christison R: Case study of lipoproteins in atherosclerosis. Edinburgh Medical Surgery Journal 1830, 33: 276-278.
24. Wasan KM, Vadiei K, Lopez-Berestein G, Luke DR: Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. Journal of Infectious Diseases 1990, 161: 562-566.
25. Wasan KM, Brazeau GA, Keyhani A, Hayman AC, Lopez-Berestein G: Role of liposome composition and temperature on the distribution of amphotericin B in serum lipoproteins. Antimicrobial Agents and Chemotherapy 1993, 37: 246-250.
26. Brajtburg J, Elberg S, Bolard J, Medoff G: Interaction of plasma proteins and lipoproteins with amphotericin B. Journal of Infectious Diseases 1984, 149: 986-992.
27. Wasan KM, Lopez-Berestein G: The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. Journal of Drug Targeting 1994, 2: 373-380.
28. Cipolle RT, Solomkin JS: Amphotericin B. In: Cipolle RT (ed): A textbook for the clinical application of therapeutic drug monitoring. Abbott, Irving, TX, 1986, p. 321-328.
29. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano RL: Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. Journal of Infectious Diseases 1983, 147: 939-945.
30. Lopez-Berestein G, Rosenblum MG, Mehta R: Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Delivery 1984, 1: 199-205.
31. Patterson TF, Andriole VT: The role of liposomal amphotericin B in the treatment of systemic fungal infections. European Journal of Cancer and Clinical Oncology 1989, 25: Supplement 1: 63-69.
32. Wasan KM, Grossie VB Jr, Lopez-Berestein G: Concentrations in serum and tissue distribution of free and liposomal amphotericin B in rats on continuous Intralipid infusion. Antimicrobial Agents and Chemotherapy 1994, 38: 2224-2226.
33. Wasan KM, Grossie VB Jr, Lopez-Berestein G: Effects of lntralipid infusion on rat serum lipoproteins. Laboratory Animals 1994, 28: 138-142.
34. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. Journal of Antimicrobial Chemotherapy 1992, 30: 535-541.
35. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N: An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. Journal of Infectious Diseases 1988, 158: 1065-1070.
36. Khutorsky VE: Structures of amphotericin B-cholesterol complex. Biochimica et Biophysica Acta 1992, 1108: 123-128.
37. Bolard J, Seigneuret M, Boudet G: Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B. Lipid state and cholesterol content dependence. Biochimica et Biophysica Acta 1980, 599: 280-293.
38. Joly V, Bolard J, Yeni P: In vitro models for studying toxicity of antifungal agents. Antimicrobial Agents and Chemotherapy 1992, 36: 1799-1808.
39. Bolard J, Vertut-Croquin A, Cybulska BE, Gary-Bobo CM: Transfer of the polyene antibiotic amphotericin B between singe-walled vesicles of dipalmitoylphosphatidylcholine and egg-yolk phosphatidylcholine. Biochimica et Biophysica Acta 1981, 647: 241-247.
40. Bolard J: How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochimica et Biophysica Acta 1986, 864: 257-266.
41. Rois A, Rosenblum M, Crofoot G, Lenk R, Hayman AC, Lopez-Berestein G: Pharmacokinetics of nystatin LF in patients with HIV infection, Journal of Infectious Diseases 1993, 168: 253-254.
42. Anaissie EJ, White M, Uzun O, Singer C, Bodey GR Matzke D, Azarnia N, Lopez-Berestein G: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective randomized multicenter trial. Proceedings from the International Association of Chemotherapy Conference 1995, International Society of Microbiology, San Diego, 1995, p. 330.
43. Boutati EI, Maltezou HC, Lopez-Berestein G, Vartivarian SE, Anaissie EJ: Phase I study of maximum tolerated dose of intravenous liposomal nystatin (L-Nyst) for the treatment of refractory febrile neutropenia (RFN) in patients with hematological malignancies. Proceedings from the International Association of Chemotherapy Conference 1995, International Society of Microbiology, San Diego, 1995, p. 330.
44. Morton RE, Zilversmit DB: Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. Journal of Lipid Research 1982, 23: 1058-1067.
45. Morton RE, Zilversmit DB: Inter-relationships of lipid transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. Journal of Biological Chemistry 1983, 258: 11,751-11,756.
46. Morton RE: Interaction of lipid transfer protein with plasma lipoproteins and cell membranes. Experimentia 1990. 46: 552-560.
47. Rajaram OV, White GH, Barter PJ: Partial purification and characterization of a triacylglycerol-transfer protein from rabbit serum. Biochimica et Biophysica Acta 1980, 617: 333-340.
48. Jarnagin AS, Kohr W, Fielding C: Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma. Proceedings of the National Academy of Sciences of the USA 1987. 84: 1854-1860.
49. Tall AR, Abreau E, Shuman J: Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. Journal of Biological Chemistry 1983, 258: 2174-2178.
50. Albers JJ, Tollefson JH, Chen C-H, Steinmetz A: Isolation and characterization of human lipid transfer proteins. Arteriosclerosis 1984, 4: 49-58.
51. Cushley RJ, Treleaven WD, Pramar YI, Chana RS, Fenske DB: Surface diffusion in human serum lipoproteins. Biochemical and Biophysical Research Communications 1987, 146: 1139-1145.
52. Surewicz WK, Epand RM, Pownall HJ, Hui SW: Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids. Journal of Biological Chemistry 1986, 261: 16,191-16,197.
53. Barwicz J, Gareau R, Audet A: Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochemical and Biophysical Research Communications 1991, 181: 722-728.
54. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G: Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high density lipoproteins: role of lipid transfer protein. Journal of Pharmaceutical Sciences 1994, 83: 1006-1010.
55. Billheimer JT, Gaylor JL: Effect of lipid composition on the transfer of sterols mediated by non-specific lipid transfer protein (sterol carrier protein 2). Biochimica et Biophysica Acta 1990, 1046: 136-143.
56. Morton RE, Steinbrunner JV: Concentration of neutral lipids in the phospholipid surface of substrate particles determines lipid transfer protein activity. Journal of Lipid Research 1990, 31: 1559-1567.
57. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G: Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrobial Agents and Chemotherapy 1994, 38: 223-227.
58. Kasi LP, Lopez-Berestein G, Mehta K: Distribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice. International Journal of Nuclear Medicine and Biology 1984, 11: 35-41.
59. Perez-Soler R, Lopez-Berestein G, Kasi L, Mehta K, Juliano RJ: Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease. Journal of Nuclear Medicine 1985, 26: 743-748.
60. Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein G: Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Experimental Chemotherapy 1994, 40: 256-264.
61. Mehta K, Lopez-Berestein G, Hersh EM, Juliano RJ: Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. Journal of Reticoendothelial Society 1982, 32: 155-163.
62. Rigaud D, Serog P, LeGrand S, Cerf M, Apfelbaum M, Bonfils S: Quantitation of lipoprotein X and its relationship to plasma lipid profile during different types of parenteral nutrition. Journal of Parenteral and Enteral Nutrition 1984, 8: 529-534.
63. Innis SM, Forhlich J, McLeod R, Allardyce BD, Hahn P: Serial measurement of plasma cholesterol and lecithin: cholesterol acyltransferase activity in adults receiving total parenteral nutrition. Journal of Parenteral and Enterai Nutrition 1985, 9: 34-37.
64. Anderson RJ, Jeffrey IJ, Kay PM, Braganza JM: Peroxidised linoleic acid and experimental pancreatitis. International Journal of Pancreatology 1986, 1: 237-248.
65. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Frankel LS, Bodey GP: Liposomal amphotericin B for the treatment of fungal infections in patients with cancer, a preliminary study. Journal of Infectious Diseases 1985, 151: 704-710.
66. Lopez-Berestein G, Bodey GR Frankel LS, Mehta K: Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. Journal of Clinical Oncology 1987, 5: 310-317.
67. Weber RS, Lopez-Berestein G: Treatment of invasive aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope 1987, 97: 937-941.
68. Lopez-Berestein G, Bodey GP, Fainstein V, Mehta K: Treatment of systemic fungal infections with liposomal amphotericin B. Archives of Internal Medicine 1989, 149: 2533-2538.
69. Janoff AS: Lipids, liposomes, and rational drug design. Laboratory Investigation 1992, 66: 655-658.
70. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP: Tissue distribution of amphotericin B lipid complex in laboratory animals. Journal of Pharmacy and Pharmacology 1991, 43: 831-835.
71. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA: Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clinical Pharmacokinetics 1992, 23: 279-291.
72. Clark JM, Whitney RR, Olsen SJ: Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrobial Agents and Chemotherapy 1991, 35: 615-621.
73. demons KV, Stevens DA: Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrobial Agents and Chemotherapy 1991, 35: 2144-2146.
74. Kan VL, Bennett JE, Amantea MA: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin deoxycholate in healthy male volunteers. Journal of Infectious Diseases 1991, 164: 418-421.
75. Allendoerfer R, Yates RR, Sun SH, Graybill JR: Comparison of amphotericin lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. Journal of Medical and Veterinarian Mycology 1992, 30: 377-384.
76. Patterson TF, Miniter R Dijkstra J: Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol sulphate complexes. Journal of Infectious Diseases 1989, 159: 717-724.
77. Gates C, Pinney RJ: Amphotericin B and its delivery by liposomal and lipid formulations. Journal of Clinical Pharmacy and Therapeutics 1993, 18: 147-153.
78. Saunders SW, Buchi KN, Goddard MS: Single-dose pharmacokinetics and tolerance of cholesterol sulphate complex of amphotericin B administered to healthy volunteers. Antimicrobial Agents and Chemotherapy 1991, 35: 1029-1034.
79. Chopra R, Blair S, Strang J: Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. Journal of Antimicrobial Agents 1991, 28: 93-104.
80. Ringden O, Meunier F, Tollemar J: Efficacy of amphotericin B (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Agents 1991, 28: 73-82.
81. Meunier F, Prentice HG, Ringden O: Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. Journal of Antimicrobial Agents 1991, 28: 83-91.
82. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology 1992, 74: 2045-2051.
83. Feingold KR, Krauss RM, Pang M, Doerrler W, Pensen P, Grunfeld C: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. Journal of Clinical Endocrinology 1993, 76: 1423-1431.
84. Vitols S, Gahrton G, Ost A, Peterson C: Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 1984, 63: 1186-1193.
85. Vitols S, Angelin B, Ericsson S, Gahrton G, Juliusson G, Masquelier M, Paul C, Peterson C, Rudling M, Soderberg-Reid K, Tidefeldt U: Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proceedings of the National Academy of Sciences of the USA 1990, 87: 2598-2602.
86. Ho YK, Smith G, Brown MS, Goldstein JL: Low density lipoprotein (LDL) receptor activity in human myelogenous leukemia cells. Blood 1978, 52: 1099-1107.
87. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G: Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrobial Agents and Chemotherapy 1994, 38: 223-227.